Bridgebio Pharma, Inc. · NASDAQ:BBIO
Farallon Capital Management, L.L.C. reported a 5.50% stake in Bridgebio Pharma, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 3, 2026
Farallon Capital Management, L.L.C. reported a 5.50% stake in Bridgebio Pharma, Inc., 10,743,063 shares, as a passive investor on Jun 30, 2026. Filed Aug 3, 2026 (Schedule 13G/A).
- Stake
- 5.50%
- Shares
- 10,743,063
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 29 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Farallon Capital Management, L.L.C. | 5.50% | 10,743,063 |
| Farallon Capital Partners, L.P. | 0% | 0 |
| Farallon Capital Institutional Partners, L.P. | 0% | 0 |
| Farallon Capital Institutional Partners II, L.P. | 0% | 0 |
| Farallon Capital Institutional Partners III, L.P. | 0% | 0 |
| Four Crossings Institutional Partners V, L.P. | 0% | 0 |
| Farallon Capital Offshore Investors II, L.P. | 0% | 0 |
| Farallon Capital (AM) Investors, L.P. | 0% | 0 |
| Farallon Capital F5 Master I, L.P. | 0% | 0 |
| Farallon Healthcare Partners Master, L.P. | 0% | 0 |
| Farallon Partners, L.L.C. | 0% | 0 |
| Farallon Institutional (GP) V, L.L.C. | 0% | 0 |
| Farallon F5 (GP), L.L.C. | 0% | 0 |
| Farallon Healthcare Partners (GP), L.L.C. | 0% | 0 |
| Dapice Joshua J. | 5.50% | 10,743,063 |
| Dreyfuss, Philip D. | 5.50% | 10,743,063 |
| Dunn Hannah E. | 5.50% | 10,743,063 |
| Gehani, Varun N. | 5.50% | 10,743,063 |
| Giauque, Nicolas | 5.50% | 10,743,063 |
| Husen, Avner A. | 5.50% | 10,743,063 |
| Kim, David T. | 5.50% | 10,743,063 |
| Linn, Michael G. | 5.50% | 10,743,063 |
| Luo Patrick (Cheng) | 5.50% | 10,743,063 |
| Roberts, Jr., Thomas G. | 5.50% | 10,743,063 |
| Saito Edric C. | 5.50% | 10,743,063 |
| Short Daniel S. | 5.50% | 10,743,063 |
| Spokes, Andrew J. M. | 5.50% | 10,743,063 |
| Warren, John R. | 5.50% | 10,743,063 |
| Wehrly, Mark C. | 5.50% | 10,743,063 |